- Home
- LFLY vs APM Comparison
LFLY vs APM Comparison
Compare LFLY & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFLY
- APM
- Stock Information
- Founded
- LFLY 2010
- APM 2010
- Country
- LFLY United States
- APM United Kingdom
- Employees
- LFLY N/A
- APM N/A
- Industry
- LFLY Computer Software: Prepackaged Software
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- LFLY Technology
- APM Health Care
- Exchange
- LFLY Nasdaq
- APM Nasdaq
- Market Cap
- LFLY 3.9M
- APM 4.0M
- IPO Year
- LFLY N/A
- APM 2018
- Fundamental
- Price
- LFLY $1.21
- APM $0.72
- Analyst Decision
- LFLY Strong Buy
- APM
- Analyst Count
- LFLY 2
- APM 0
- Target Price
- LFLY $7.59
- APM N/A
- AVG Volume (30 Days)
- LFLY 32.7K
- APM 69.7K
- Earning Date
- LFLY 11-07-2024
- APM 12-27-2024
- Dividend Yield
- LFLY N/A
- APM N/A
- EPS Growth
- LFLY N/A
- APM N/A
- EPS
- LFLY N/A
- APM N/A
- Revenue
- LFLY $35,868,000.00
- APM $431,378.00
- Revenue This Year
- LFLY N/A
- APM $157,729.10
- Revenue Next Year
- LFLY N/A
- APM N/A
- P/E Ratio
- LFLY N/A
- APM N/A
- Revenue Growth
- LFLY N/A
- APM N/A
- 52 Week Low
- LFLY $1.20
- APM $0.46
- 52 Week High
- LFLY $5.88
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- LFLY 34.88
- APM 41.12
- Support Level
- LFLY $1.20
- APM $0.73
- Resistance Level
- LFLY $1.35
- APM $0.78
- Average True Range (ATR)
- LFLY 0.08
- APM 0.09
- MACD
- LFLY 0.00
- APM 0.04
- Stochastic Oscillator
- LFLY 16.92
- APM 64.47
About LFLY Leafly Holdings Inc.
Leafly Holdings Inc operates an online cannabis information resource platform. It offers cannabis retailers and brands subscription-based marketplace listings that provide its cannabis audience with information, reviews, menus, and ordering and delivery options through legal retailers.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.